Lumateperone Leads Efficacy While Aripiprazole Shows Best Acceptability in Depression

Navigating the Complexity of Antidepressant Augmentation

Achieving full symptomatic remission remains a significant challenge in the management of major depressive disorder, as many patients do not respond adequately to initial antidepressant monotherapy [1, 2]. When first-line agents fail, clinicians often utilize adjunctive strategies, with atypical antipsychotics currently holding the highest level of evidence for efficacy in treatment-resistant cases [1, 3, 4]. While these agents can significantly improve response and remission rates, with one meta-analysis of 3,480 patients showing a remission odds ratio of 2.00 (95% CI 1.69 to 2.37), their clinical utility is frequently limited by adverse effects that lead to high rates of treatment discontinuation [5, 6, 3]. Selecting the appropriate agent requires a careful weighing of potential metabolic risks, extrapyramidal symptoms (drug-induced movement disorders such as akathisia or tremors), and overall patient tolerability [7, 8]. To help clinicians optimize these difficult treatment decisions, a systematic review and meta-analysis of 22 short-term studies involving 10,962 participants now provides a comparative hierarchy of five antipsychotics approved by the US Food and Drug Administration for adjunctive use [6].

Quantifying Efficacy Across Five FDA-Approved Agents

Most adults living with major depressive disorder fail to achieve remission when treated with conventional antidepressant monotherapy. To address this clinical gap, the US Food and Drug Administration (FDA) has approved five atypical antipsychotics for use as adjunctive treatments. To compare these agents, researchers conducted a systematic search of major medical databases through July 15, 2025. The study employed a rigorous methodology where independent raters screened publications, extracted data, and assessed the risk of bias using Cochrane criteria. The researchers then synthesized effect sizes using random-effects models (a statistical method that accounts for variation between different study populations and designs). The primary efficacy outcome was defined as a 50% or greater reduction from baseline in the total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a standard clinician-rated tool used to measure the severity of depressive episodes. Among the five agents, lumateperone demonstrated the highest effect size for efficacy with a risk ratio (RR) of 1.72 (95% credible interval [CrI], a Bayesian statistical measure similar to a confidence interval, 1.40 to 2.15). This was followed by aripiprazole, which showed a risk ratio of 1.53 (95% CrI, 1.32 to 1.77). The remaining three agents also showed varying degrees of symptom reduction compared to placebo: brexpiprazole (RR, 1.38; 95% CrI, 1.18 to 1.65), cariprazine (RR, 1.20; 95% CrI, 1.07 to 1.36), and quetiapine extended release (XR) (RR, 1.15; 95% CrI, 0.96 to 1.35). For the practicing physician, these risk ratios represent the probability of achieving a meaningful clinical response when the specific antipsychotic is added to standard antidepressant therapy, providing a clear hierarchy of expected symptom relief.

The Acceptability Gap and Patient Adherence

While symptom reduction is a critical metric for clinical success, the long-term utility of an adjunctive agent depends heavily on its acceptability, which the researchers defined as all-cause discontinuation. This metric serves as a proxy for treatment adherence and patient tolerance, representing the rate at which participants stop taking the medication for any reason, including adverse effects or a lack of perceived benefit. The meta-analysis revealed a distinct hierarchy of acceptability that often diverged from the efficacy rankings. Aripiprazole exhibited the highest acceptability among the five agents, with a risk ratio of 1.16 (95% CrI, 0.89 to 1.50). This suggests that patients were most likely to remain on aripiprazole therapy compared to the other atypical antipsychotics evaluated in the study. In stark contrast, the agent with the highest efficacy, lumateperone, exhibited the lowest acceptability with a risk ratio of 2.30 (95% CrI, 1.45 to 3.84). This significant gap suggests that while lumateperone may provide robust symptom relief for those who tolerate it, clinicians must carefully monitor for side effects that might lead to early discontinuation. The remaining three agents occupied a middle ground in terms of patient adherence. Cariprazine showed an acceptability risk ratio of 1.44 (95% CrI, 1.15 to 1.82), followed closely by brexpiprazole at 1.47 (95% CrI, 1.18 to 1.85). Quetiapine XR demonstrated a risk ratio of 1.56 (95% CrI, 1.14 to 2.12). These findings emphasize that the selection of an adjunctive antipsychotic requires a balanced consideration of both the probability of response and the likelihood that the patient will actually continue the prescribed regimen.

Clinical Implications and Evidence Gaps

The findings of this meta-analysis are derived from a robust dataset of 22 short-term studies comprising a total of 10,962 participants, providing a high level of statistical power for comparing adjunctive therapies. The distribution of the study population included 1,297 patients treated with aripiprazole, 1,973 with brexpiprazole, 1,894 with cariprazine, 483 with lumateperone, and 719 with quetiapine XR, while 4,596 participants received a placebo. This large-scale aggregation allows clinicians to move beyond individual trial data to see how these five FDA-approved agents compare in a head-to-head statistical framework. Beyond the primary metrics of response and discontinuation, the researchers found that secondary outcomes, such as symptomatic remission (the near-complete resolution of depressive symptoms), and exploratory outcomes, including clinically significant weight gain, accorded with the coprimary outcomes. This consistency suggests that the efficacy and acceptability hierarchies identified in the study are reliable indicators of overall clinical performance. A critical consideration for long-term management, however, is the absence of adequate and well-controlled studies documenting the maintenance efficacy of adjunctive atypical antipsychotics in major depressive disorder. While the current data provide clear guidance for acute stabilization, there is a significant knowledge gap regarding the duration of treatment required once a patient achieves stability. Because the included trials were short-term, clinicians must exercise clinical judgment when deciding how long to maintain an adjunctive antipsychotic, carefully balancing the risk of depressive relapse against the potential for long-term adverse effects. The selection of an agent should therefore be a dynamic process that considers both the immediate need for symptom reduction and the patient's long-term tolerance of the medication.

References

1. Adelino MPM, Grossi JD, Nunes MV, et al. Brazilian Psychiatric Association Guidelines for pharmacological treatment of Major Depressive Disorder: An overview of systematic reviews and meta-analyses.. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2026. doi:10.47626/1516-4446-2026-4911

2. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder.. Psychopharmacology bulletin. 2025. doi:10.64719/pb.4089

3. Yan Y, Yang X, Wang M, Chen B, Yin L, Ma X. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.. Psychological medicine. 2022. doi:10.1017/S0033291722001246

4. Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk W. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials.. The international journal of neuropsychopharmacology. 2015. doi:10.1093/ijnp/pyv023

5. Nelson JC, Papakostas GI. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Psychiatry. 2009. doi:10.1176/appi.ajp.2009.09030312

6. McIntyre RS, Stahl SM, Shim SR, et al. Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.. JAMA psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0658

7. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis. World Psychiatry. 2015. doi:10.1002/wps.20252

8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine. 2005. doi:10.1056/nejmoa051688